Frontlight ResearchEarly access
Graves' disease trials in Argentina
1 of 1 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
- Where
- Buenos Aires, Córdoba
- Age
- 18 years to 75 years
- People
- 30 worldwide
- Run by
- Sanofi
See details and how to joinNCT06984627